SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.

E Wangeci Kagucia ORCID logo ; Abdhala K Ziraba ; James Nyagwange ; Bernadette Kutima ; Makobu Kimani ; Donald Akech ; Maurine Ng'oda ; Antipa Sigilai ; Daisy Mugo ; Henry Karanja ; +28 more... John Gitonga ; Angela Karani ; Monica Toroitich ; Boniface Karia ; Mark Otiende ORCID logo ; Anne Njeri ; Rashid Aman ; Patrick Amoth ; Mercy Mwangangi ; Kadondi Kasera ; Wangari Ng'ang'a ; Shirine Voller ORCID logo ; Lynette I Ochola-Oyier ; Christian Bottomley ORCID logo ; Amek Nyaguara ; Patrick K Munywoki ; Godfrey Bigogo ; Eric Maitha ; Sophie Uyoga ; Katherine E Gallagher ORCID logo ; Anthony O Etyang ; Edwine Barasa ; Joseph Mwangangi ; Philip Bejon ; Ifedayo MO Adetifa ORCID logo ; George M Warimwe ; J Anthony G Scott ORCID logo ; Ambrose Agweyu ORCID logo ; (2023) SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022. Influenza and other respiratory viruses, 17 (9). e13173-. ISSN 1750-2640 DOI: 10.1111/irv.13173
Copy

BACKGROUND: We sought to estimate SARS-CoV-2 antibody seroprevalence within representative samples of the Kenyan population during the third year of the COVID-19 pandemic and the second year of COVID-19 vaccine use. METHODS: We conducted cross-sectional serosurveys among randomly selected, age-stratified samples of Health and Demographic Surveillance System (HDSS) residents in Kilifi and Nairobi. Anti-spike (anti-S) immunoglobulin G (IgG) serostatus was measured using a validated in-house ELISA and antibody concentrations estimated with reference to the WHO International Standard for anti-SARS-CoV-2 immunoglobulin. RESULTS: HDSS residents were sampled in February-June 2022 (Kilifi HDSS N = 852; Nairobi Urban HDSS N = 851) and in August-December 2022 (N = 850 for both sites). Population-weighted coverage for ≥1 doses of COVID-19 vaccine were 11.1% (9.1-13.2%) among Kilifi HDSS residents by November 2022 and 34.2% (30.7-37.6%) among Nairobi Urban HDSS residents by December 2022. Population-weighted anti-S IgG seroprevalence among Kilifi HDSS residents increased from 69.1% (65.8-72.3%) by May 2022 to 77.4% (74.4-80.2%) by November 2022. Within the Nairobi Urban HDSS, seroprevalence by June 2022 was 88.5% (86.1-90.6%), comparable with seroprevalence by December 2022 (92.2%; 90.2-93.9%). For both surveys, seroprevalence was significantly lower among Kilifi HDSS residents than among Nairobi Urban HDSS residents, as were antibody concentrations (p < 0.001). CONCLUSION: More than 70% of Kilifi residents and 90% of Nairobi residents were seropositive for anti-S IgG by the end of 2022. There is a potential immunity gap in rural Kenya; implementation of interventions to improve COVID-19 vaccine uptake among sub-groups at increased risk of severe COVID-19 in rural settings is recommended.


picture_as_pdf
Kagucia-etal-2023-SARS-CoV-2-seroprevalence-and-implications-for-population-immunity.pdf
subject
Published Version
copyright
Available under Copyright the author(s)

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads